AstraZeneca Pharma India Limited
NSE: ASTRAZEN BSE: ASTRAZEN
NSE
9,302.50
1.50 (0.02%)
Prev Close
9301
Open Price
9283
Volume
4,126
Today Low / High
9250.5 / 9360
52 WK Low / High
6220 / 10691
Range
8,837 - 9,768
BSE
9,290.25
-11.20 (-0.12%)
Prev Close
9301.45
Open Price
9277.95
Volume
310
Today Low / High
9262.85 / 9341.3
52 WK Low / High
6222.35 / 10653.05
Range
8,826 - 9,755
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 9302.5 (target range: 8,837 - 9,768), reflecting a change of 1.5 (0.0161273%). On the BSE, it is listed at 9290.25 (target range: 8,826 - 9,755), showing a change of -11.2 (-0.12041%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
24 Oct
9,283.00
0.21%
23 Oct
9,306.00
-0.05%
21 Oct
9,350.00
-0.47%
20 Oct
9,140.50
2.23%
17 Oct
9,061.00
1.30%
16 Oct
9,151.00
-0.55%
15 Oct
9,121.00
0.30%
14 Oct
9,222.50
-1.10%
13 Oct
9,324.50
-1.09%
10 Oct
9,270.00
-0.09%
09 Oct
9,270.00
-0.30%
08 Oct
9,330.50
-0.59%
07 Oct
9,370.00
0.12%
06 Oct
9,339.00
0.81%
03 Oct
9,248.00
0.90%
01 Oct
9,100.00
1.34%
30 Sep
8,833.00
3.09%
29 Sep
8,812.00
0.90%
AstraZeneca Pharma India Limited Graph
AstraZeneca Pharma India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for AstraZeneca Pharma India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 9,302.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 9,290.25 | 9,383.15 | 8,444.84 - 10,321.47 |
| 9,476.06 | 7,580.84 - 11,371.27 | ||
| 9,568.96 | 6,698.27 - 12,439.64 | ||
| Bearish Scenario | 9,290.25 | 9,197.35 | 8,277.61 - 10,117.08 |
| 9,104.45 | 7,283.56 - 10,925.33 | ||
| 9,011.54 | 6,308.08 - 11,715.01 |
Overview of AstraZeneca Pharma India Limited
ISIN
INE203A01020
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
20,343
Market Cap
232,562,500,000
Last Dividend
32
Official Website
IPO Date
2002-07-01
DCF Diff
-9,501.07
DCF
18,804
Financial Ratios Every Investor Needs
Stock Dividend of ASTRAZEN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-18 | July 18, 25 | 32 | 32 | 2025-07-18 | 2025-09-12 | |
| 2024-07-05 | July 05, 24 | 24 | 24 | 2024-07-05 | 2024-09-06 | |
| 2023-07-14 | July 14, 23 | 16 | 16 | 2023-07-14 | 2023-09-13 | |
| 2022-07-07 | July 07, 22 | 8 | 8 | 2022-07-08 | 2022-09-06 | |
| 2021-08-18 | August 18, 21 | 2 | 2 | 2021-08-20 | 2021-09-07 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,716.29 Cr | 963.01 Cr | 753.28 Cr | 0.4389 | 31.24 Cr | 50.94 Cr | 213.98 Cr | 115.74 Cr | 46.30 | 197.81 Cr | 0.0674 |
| 2024-03-31 | 1,295.53 Cr | 673.26 Cr | 622.27 Cr | 0.4803 | 72.86 Cr | 42.15 Cr | 171.43 Cr | 161.51 Cr | 64.60 | 235.68 Cr | 0.1247 |
| 2023-03-31 | 1,002.97 Cr | 425.26 Cr | 577.71 Cr | 0.5760 | 0.00 Cr | 29.93 Cr | 148.89 Cr | 99.29 Cr | 39.72 | 150.99 Cr | 0.0990 |
| 2022-03-31 | 805.60 Cr | 357.46 Cr | 448.14 Cr | 0.5563 | 0.00 Cr | 28.00 Cr | 69.65 Cr | 61.60 Cr | 24.64 | 100.94 Cr | 0.0765 |
| 2021-03-31 | 808.56 Cr | 330.54 Cr | 478.02 Cr | 0.5912 | 28.76 Cr | 31.89 Cr | 116.26 Cr | 93.30 Cr | 37.32 | 147.93 Cr | 0.1154 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 536.14 Cr | 1,518.12 Cr | 747.77 Cr | 770.3500 Cr | 35.73 Cr | -500.41 Cr | 548.50 Cr | 63.58 Cr | 0.00 Cr | 9.00 Cr | 3.76 Cr | 703.0000 Cr |
| 2024-03-31 | 505.57 Cr | 1,078.03 Cr | 366.11 Cr | 711.9200 Cr | 4.59 Cr | -500.98 Cr | 227.88 Cr | 64.84 Cr | 49.61 Cr | 0.00 Cr | 0.27 Cr | 357.1200 Cr |
| 2023-03-31 | 500.34 Cr | 984.87 Cr | 396.20 Cr | 588.6900 Cr | 7.21 Cr | -493.12 Cr | 190.21 Cr | 70.19 Cr | 40.17 Cr | 0.00 Cr | 0.88 Cr | 383.9300 Cr |
| 2022-03-31 | 448.42 Cr | 856.56 Cr | 345.17 Cr | 511.3900 Cr | 8.63 Cr | -439.79 Cr | 140.22 Cr | 76.69 Cr | 30.69 Cr | 0.00 Cr | 0.00 Cr | 332.6500 Cr |
| 2021-03-31 | 352.34 Cr | 774.71 Cr | 318.54 Cr | 456.1700 Cr | 12.14 Cr | -340.20 Cr | 159.80 Cr | 84.98 Cr | 12.83 Cr | 0.00 Cr | 0.00 Cr | 303.5000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 65.3600 Cr | 30.8000 Cr | -65.5900 Cr | 63.6100 Cr | 30.5700 Cr | 536.1400 Cr | -1.7500 Cr | 156.3600 Cr | -4.1300 Cr | -60.0000 Cr | -320.6200 Cr |
| 2024-03-31 | 27.8700 Cr | 21.7400 Cr | -44.3800 Cr | 17.1100 Cr | 5.2300 Cr | 505.5700 Cr | -10.7600 Cr | 161.5100 Cr | -3.8600 Cr | -40.0000 Cr | -37.6679 Cr |
| 2023-03-31 | 58.2900 Cr | 18.1100 Cr | -24.4800 Cr | 49.7700 Cr | 51.9200 Cr | 500.3400 Cr | -8.5200 Cr | 134.1000 Cr | -3.8500 Cr | -20.0000 Cr | -49.9948 Cr |
| 2022-03-31 | 100.8000 Cr | 4.7400 Cr | -9.4600 Cr | 91.1800 Cr | 96.0800 Cr | 448.4200 Cr | -9.6200 Cr | 83.0400 Cr | -3.5100 Cr | -5.0000 Cr | 19.5800 Cr |
| 2021-03-31 | 104.7800 Cr | 173.0300 Cr | -8.9700 Cr | 97.0700 Cr | 268.8400 Cr | 352.3400 Cr | -7.7100 Cr | 127.0900 Cr | -2.8800 Cr | -5.0000 Cr | 5.3500 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 526.31 Cr | 295.41 Cr | 230.90 Cr | 0.4387 | 64.54 Cr | 55.83 Cr | 22.33 | 91.99 Cr | 0.1061 |
| 2025-03-31 | 480.48 Cr | 259.61 Cr | 220.87 Cr | 0.4597 | 68.68 Cr | 58.25 Cr | 23.30 | 96.84 Cr | 0.1212 |
| 2024-12-31 | 440.29 Cr | 247.03 Cr | 193.26 Cr | 0.4389 | 67.92 Cr | 30.85 Cr | 12.34 | 51.42 Cr | 0.0701 |
| 2024-09-30 | 408.00 Cr | 225.93 Cr | 182.07 Cr | 0.4463 | 43.20 Cr | 38.43 Cr | 15.37 | 60.69 Cr | 0.0942 |
| 2024-06-30 | 387.52 Cr | 295.31 Cr | 92.21 Cr | 0.2379 | 34.16 Cr | -11.79 Cr | -4.72 | -11.14 Cr | -0.0304 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 536.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -770.35 Cr |
| 2025-03-31 | 536.14 Cr | 16.36 Cr | 552.50 Cr | 185.18 Cr | 548.50 Cr | 1,342.35 Cr | 63.58 Cr | 1,518.12 Cr | 747.77 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 496.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -679.35 Cr |
| 2024-09-30 | 496.52 Cr | 11.45 Cr | 507.97 Cr | 150.09 Cr | 381.99 Cr | 1,066.53 Cr | 67.46 Cr | 1,241.30 Cr | 561.95 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 505.57 Cr | 0.00 Cr | 0.00 Cr | 505.57 Cr | 0.00 Cr | 0.00 Cr | -711.92 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 55.83 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 58.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 30.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 38.43 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -11.79 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2006-06-15 | June 15, 06 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,699.00 | ₹4,076,463,958,553.00 | ₹994,091.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,593.00 | ₹1,750,239,833,316.00 | ₹250,637.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,581.40 | ₹1,212,106,923,000.00 | ₹95,316.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,283.60 | ₹1,068,422,526,670.00 | ₹1,167,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,004.90 | ₹1,011,160,085,849.00 | ₹583,308.00 |
| Mankind Pharma Limited | MANKIND | ₹2,432.40 | ₹1,003,993,751,076.00 | ₹249,565.00 |
| Lupin Limited | LUPIN | ₹1,931.20 | ₹882,090,794,682.00 | ₹465,756.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,545.00 | ₹662,987,925,000.00 | ₹117,663.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,085.00 | ₹630,169,760,955.00 | ₹761,529.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,818.80 | ₹513,266,831,409.00 | ₹536,263.00 |
| Laurus Labs Limited | LAURUSLABS | ₹926.40 | ₹500,093,786,434.00 | ₹8,916,465.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹876.40 | ₹335,281,841,496.00 | ₹175,527.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,268.70 | ₹321,874,541,377.00 | ₹123,050.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,414.40 | ₹301,644,570,586.00 | ₹198,786.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.20 | ₹266,558,118,026.00 | ₹95,511.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,302.50 | ₹232,562,500,000.00 | ₹4,126.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,332.40 | ₹216,494,748,852.00 | ₹228,979.00 |
| Eris Lifesciences Limited | ERIS | ₹1,582.60 | ₹215,571,570,560.00 | ₹71,836.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,088.00 | ₹206,407,254,232.00 | ₹20,551.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹924.60 | ₹181,742,264,450.00 | ₹124,978.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,118.60 | ₹177,354,906,982.00 | ₹165,729.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,993.10 | ₹151,498,911,298.00 | ₹39,825.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹824.90 | ₹147,747,731,763.00 | ₹237,400.00 |
| Granules India Limited | GRANULES | ₹564.55 | ₹136,998,623,618.00 | ₹550,931.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,083.50 | ₹100,982,340,397.00 | ₹8,487.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹832.40 | ₹75,442,883,396.00 | ₹80,920.00 |
| Strides Pharma Science Limited | STAR | ₹814.55 | ₹75,079,284,189.00 | ₹155,978.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹363.60 | ₹71,113,548,298.00 | ₹116,240.00 |
| FDC Limited | FDC | ₹430.25 | ₹70,049,038,641.00 | ₹337,390.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.06 | ₹50,497,390,269.00 | ₹494,753.00 |
| Innova Captab Limited | INNOVACAP | ₹805.30 | ₹46,083,235,324.00 | ₹22,392.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹493.95 | ₹45,082,816,500.00 | ₹94,285.00 |
| Suven Life Sciences Limited | SUVEN | ₹199.66 | ₹43,534,005,563.00 | ₹151,167.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹131.37 | ₹42,632,401,016.00 | ₹115,027.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,354.80 | ₹38,946,072,522.00 | ₹11,359.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹720.25 | ₹36,530,435,376.00 | ₹36,029.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹341.70 | ₹34,266,532,300.00 | ₹35,695.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹469.10 | ₹33,027,337,325.00 | ₹7,482.00 |
| Hikal Limited | HIKAL | ₹243.00 | ₹29,962,082,250.00 | ₹92,590.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹92.90 | ₹27,268,705,679.00 | ₹1,191,807.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹48.84 | ₹26,762,058,659.00 | ₹986,159.00 |
| Indoco Remedies Limited | INDOCO | ₹281.35 | ₹25,929,723,837.00 | ₹77,952.00 |
| Alembic Limited | ALEMBICLTD | ₹100.80 | ₹25,883,608,262.00 | ₹163,514.00 |
Key Executives
Vice President of Human Resources
Ms. Smita Saha
Gender: female
Year Born: 1970
Interim Business Unit Head of Oncology & Director of Commercial Excellence
Mr. Ayush Kumar Agarwal
Gender: male
Year Born:
Legal Counsel
Mr. Pratap Rudra Bhuvanagiri
Gender: male
Year Born:
Legal Head
Mr. Pankaj S Jain
Gender: male
Year Born:
Head of Oncology Business Unit
Mr. Praveen Akkinepally
Gender: male
Year Born:
Company Secretary & Compliance Officer
Ms. Manasa R.
Gender: female
Year Born:
Business Unit Head - Rare Disease unit
Mr. Vinay Sharma
Gender: male
Year Born:
Whole-Time Director & Chief Financial Officer
Ms. Bhavana Agrawal
Gender: female
Year Born:
MD, Country President & Director
Dr. Sanjeev Kumar Panchal
Gender: Not Specified
Year Born: 1977
FAQs about AstraZeneca Pharma India Limited
Who is the CEO of the company?
The CEO is Sanjeev Kumar Panchal.
What is the current market price of the stock?
The current price is ₹9,302.50.
What is the 52-week price range?
The range is ₹6220-10691.
What is the market capitalization of the company?
The market capitalization is ₹23,256.25 crores.
What is the dividend yield?
The dividend yield is 0.34%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 126.85.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of AstraZeneca Pharma India Limited (ISIN: INE203A01020) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹23,256.25 crores and an average daily volume of 20,343 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹32.